Microwave Ablation of Colorectal Cancer Lung Metastases: Single Center 10-year Experience

Tuesday, March 7, 2023

3:45 PM – 3:54 PM

Location: Phoenix Convention Center, 221AB

Presenting Author(s)

Timothy M. Cooke, BS

Medical Student
Memorial Sloan Kettering Cancer Center

Disclosure(s): No financial relationships to disclose

Author/Co-author(s)

Vlasios S. Sotirchos, MD

Assistant Attending
Memorial Sloan Kettering Cancer Center
JE

Joseph P. Erinjeri, MD PhD

Attending
Memorial Sloan Kettering Cancer Center
NP

Nadia N. Petre, MD

Senior Research Scientist
Memorial Sloan Kettering Cancer Center
Constantinos T. Sofocleous, MD PhD

Professor IR
Weill Cornell Medical College Memorial Sloan-Kettering Cancer Center
SS

Stephen B. Solomon, MD

Section Chief
Memorial Sloan Kettering Cancer Center

Disclosure(s):

Timothy M. Cooke, BS: No financial relationships to disclose

Vlasios S. Sotirchos, MD: No financial relationships to disclose

Constantinos T. Sofocleous, MD PhD: No relevant disclosure to display

Stephen B. Solomon, MD: Aperture Medical: Board Membership (Ongoing), Consultant (Ongoing), Ownership Interest (Ongoing); Elesta: Research Grant Recipient (Ongoing); GE Healthcare: Consultant (Ongoing), Research Grant Recipient (Ongoing); Johnson & Johnson: Consultant (Ongoing), Ownership Interest (Ongoing); Microbot: Consultant (Ongoing); XAct Robotics: Consultant (Ongoing)

Purpose: To review oncologic outcomes following microwave ablation (MWA) of colorectal cancer lung metastases.

Materials and Methods: This study consisted of an institutional review board-approved, HIPAA-compliant retrospective review of patients undergoing MWA for colorectal lung metastases between January 2011 and December 2021 at a single institution. Imaging follow-up included a chest CT at 4-8 weeks post-MWA, with subsequent cross-sectional imaging every 2-4 months. Overall survival (OS) and local tumor progression-free survival (LTPFS) were calculated using the Kaplan-Meier method. Predictors of LTPFS were evaluated using the log-rank test.

Results: A total of 716 lung metastases in 271 patients were treated with MWA. Median lung tumor size was 0.8 cm (range 0.3-3.5 cm). Median OS was 47 months (95% CI: 32.9-61.3). LTPFS at 1, 2 and 3-years was 91.6%, 83.5% and 73.9% respectively. Tumors ≥1 cm in size, pleural-based tumors and pre-MWA CEA levels >10 ng/mL were associated with shorter LTPFS (all p< 0.001).

Conclusion: MWA of colorectal cancer lung metastases is associated with high local tumor control rates, especially in patients with subcentimeter, non-pleural based tumors and with low pre-MWA CEA levels.